Bartal MF, Ward C, Blackwell SC, et al. - Researchers investigated the probability of reduction in the risk for adverse neonatal outcome in correlation with treatment with insulin detemir vs neutral protamine Hagedorn (NPH) among individuals with type 2 diabetes mellitus or overt type 2 (gestational diabetes diagnosis < 20 weeks). In this multiclinic randomized controlled trial, singleton gestation with type 2 diabetes or overt type 2 who sought obstetrical care ≤ 21 weeks were included and randomized to receive either insulin detemir or NPH by a clinic-stratified scheme. They randomized a total of 108 people in this trial (57 insulin detemir; 51 NPH). Outcomes revealed lower rates of adverse neonatal and maternal outcomes in correlation with using insulin detemir vs NPH.